EVANSTON, Ill., April 29 /PRNewswire/ -- Northfield Laboratories Inc.
(Nasdaq: NFLD), a leading developer of an oxygen-carrying blood substitute,
will present data from its clinical studies to the U.S. Department of Health
and Human Services (HHS) Advisory Committee on Blood Safety and Availability,
on Friday in Bethesda, Md. The committee will examine the extent of the
nation's reserves of blood and blood products, and make a formal
recommendation to HHS on its findings.
Northfield's scientists will discuss the company's expectations for the
role of blood substitutes as an alternative or reserve blood supply.
Additionally, Northfield will describe results of studies in trauma,
demonstrating an increase in survival in patients suffering from blood loss
who received the company's blood substitute, PolyHeme(TM).
PolyHeme(TM) is the only blood substitute undergoing clinical trials
that has been tested at large enough dosages to be considered a substitute
for acute blood loss in trauma and surgical settings, according to
Northfield. As a result of the process used to manufacture the blood
substitute -- essentially a solution of polymerized hemoglobin, PolyHeme(TM)
has a longer shelf life than blood, requires no cross matching and does not
transmit disease.
Northfield Laboratories was founded in 1985. The company is headquartered
in Evanston, Illinois, and its stock is traded on the Nasdaq National Market
System under the symbol NFLD.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks, which may cause
the company's actual results in the future to differ materially from expected
results. These risks include, among others: competition from other blood
substitute products; the company's ability to obtain regulatory approval to
market PolyHeme(TM) commercially; the company's and/or its representative's
ability to successfully market and sell PolyHeme(TM); the company's ability to
manufacture PolyHemea in sufficient quantities; the company's ability to
obtain an adequate supply of raw materials; the company's ability to maintain
intellectual property protection for its proprietary product and to defend its
existing intellectual property rights from challenges by third parties; the
availability of capital to finance planned growth; and the extent to which the
hospitals and physicians using PolyHeme(TM) are able to obtain third-party
reimbursement, as described in the company's filing with the Securities and
Exchange Commission.
Visit the Northfield web site at: http://www.northfieldlabs.com
SOURCE Northfield Laboratories, Inc.
 back to top
Related links:
http://www.northfieldlabs.com
CONTACT:
Richard DeWoskin, Chief Executive Officer of
Northfield Laboratories Inc., 847-864-3500; or General Info.,
Leslie Hunziker, Media, Bess Gallanis, or Analysts-Brokers,
Kathy Brunson, all of The Financial Relations Board, 312-266-7800
|
